Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to -$180.4 million.

  • Ultragenyx Pharmaceutical's Profit After Tax fell 3512.46% to -$180.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$579.8 million, marking a year-over-year decrease of 372.83%. This contributed to the annual value of -$569.2 million for FY2024, which is 617.43% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Profit After Tax is -$180.4 million, which was down 3512.46% from -$115.0 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Profit After Tax registered a high of -$73.0 million during Q3 2021, and its lowest value of -$245.1 million during Q3 2022.
  • Moreover, its 5-year median value for Profit After Tax was -$151.1 million (2025), whereas its average is -$146.5 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first crashed by 58361.84% in 2021, then soared by 3486.53% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Profit After Tax (Quarter) stood at -$122.5 million in 2021, then decreased by 23.99% to -$151.8 million in 2022, then increased by 18.86% to -$123.2 million in 2023, then dropped by 8.28% to -$133.4 million in 2024, then crashed by 35.26% to -$180.4 million in 2025.
  • Its Profit After Tax was -$180.4 million in Q3 2025, compared to -$115.0 million in Q2 2025 and -$151.1 million in Q1 2025.